XGN

Exagen Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth 3/10
  • Momentum 1/10
Exagen sales and earnings growth
XGN Growth
Neutral
  • Revenue Y/Y 14.08%
  • EPS Y/Y 2.13%
  • FCF Y/Y -91.19%
Exagen gross and profit margin trends
XGN Profitability
Neutral
  • Gross margin 59.90%
  • EPS margin -29.90%
  • ROIC -39.30%
Exagen net debt vs free cash flow
XGN Risk
Great
  • Debt / Equity 1.6
  • Debt / FCF 0.0
  • Interest coverage -4.3

Exagen stock volatility is in-line with the overall market. We give it a Great risk rating.

More Diagnostics & Research stocks ↗